We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+19.15%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$2.8B
AUM Growth
+$346M
Cap. Flow
-$15.3M
Cap. Flow %
-0.55%
Top 10 Hldgs %
76.91%
Holding
52
New
1
Increased
6
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$31.8M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$30.5M
3
CBIO
Crescent Biopharma
CBIO
+$27.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$11.7M
5
VSTM icon
Verastem
VSTM
+$8.17M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$36.5M
2
VERV
Verve Therapeutics
VERV
+$31.6M
3
ITOS
iTeos Therapeutics
ITOS
+$18.4M
4
XOMA
Xoma
XOMA
+$9.41M
5
THRD
Third Harmonic Bio
THRD
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.04B
$932M 33.31%
19,751,284
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$9.41B
$240M 8.58%
5,502,710
+340,909
+7% +$11.7M
RVMD icon
3
Revolution Medicines
RVMD
$43.9B
$183M 6.55%
4,982,384
– –
PTGX icon
4
Protagonist Therapeutics
PTGX
$9.28B
$177M 6.34%
3,211,041
+636,026
+25% +$30.5M
AXSM icon
5
Axsome Therapeutics
AXSM
$10.7B
$176M 6.3%
1,690,221
– –
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.1B
$141M 5.02%
2,761,333
-35,180
-1% -$1.57M
GHRS icon
7
GH Research
GHRS
$1.89B
$108M 3.84%
8,827,712
– –
IONS icon
8
Ionis Pharmaceuticals
IONS
$7.85B
$75.6M 2.7%
1,913,385
– –
XOMA
9
DELISTED
Xoma
XOMA
$65.3M 2.33%
2,590,303
-392,723
-13% -$9.41M
ZYME icon
10
Zymeworks
ZYME
$1.86B
$54.1M 1.93%
4,308,935
– –
SEPN
11
Septerna Inc
SEPN
$1.81B
$46.5M 1.66%
4,396,124
– –
CELC icon
12
Celcuity
CELC
$4.05B
$46.3M 1.65%
3,466,000
– –
KURA icon
13
Kura Oncology
KURA
$1.01B
$44.7M 1.6%
7,754,129
– –
CGEM icon
14
Cullinan Oncology
CGEM
$1.32B
$43.3M 1.55%
5,750,683
– –
ACIU icon
15
AC Immune
ACIU
$266M
$40.2M 1.44%
19,822,436
– –
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$38.3M 1.37%
786,392
-138,250
-15% -$3.32M
TYRA icon
17
Tyra Biosciences
TYRA
$1.52B
$37.7M 1.35%
3,944,194
– –
GPCR icon
18
Structure Therapeutics
GPCR
$2.78B
$36.7M 1.31%
1,771,417
– –
IMCR icon
19
Immunocore
IMCR
$1.64B
$32.1M 1.15%
+1,024,288
New +$31.8M
GLUE icon
20
Monte Rosa Therapeutics
GLUE
$1.11B
$25.5M 0.91%
5,660,132
– –
FHTX icon
21
Foghorn Therapeutics
FHTX
$245M
$24.9M 0.89%
5,302,000
– –
OLMA icon
22
Olema Pharmaceuticals
OLMA
$856M
$22.6M 0.81%
5,295,893
– –
CBIO
23
Crescent Biopharma
CBIO
$698M
$22.4M 0.8%
1,387,863
+1,292,420
+1,354% +$27.3M
XNCR icon
24
Xencor
XNCR
$1.77B
$21.5M 0.77%
2,740,141
– –
FDMT icon
25
4D Molecular Therapeutics
FDMT
$753M
$17.2M 0.61%
4,629,289
+68,000
+1% +$239K
1
2 3

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q2 2025 Portfolio in Review

As of Q2 2025, BVF Inc held 52 positions worth $2.8B, up 14% from $2.45B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

BVF Inc's Q2 2025 filing shows 1 new, 6 increased, 7 reduced and 8 closed positions. Its largest new stake was Immunocore: 1,024,288 shares worth $32.1M. The largest sale was Lakefront Biotherapeutics American Depositary Shares, an estimated $36.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q2 2025 buy was Immunocore: 1,024,288 shares worth $32.1M.
  • BVF Inc added most to Protagonist Therapeutics in Q2 2025, an estimated $30.5M increase.
  • BVF Inc's biggest Q2 2025 reduction was Xoma, cutting an estimated $9.41M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q2 2025, selling an estimated $36.5M.
  • BVF Inc's ten largest holdings make up 77% of its $2.8B portfolio in Q2 2025.
  • BVF Inc opened 1 new position and closed 8 in Q2 2025.
  • BVF Inc's portfolio value rose 14% quarter-over-quarter to $2.8B.

Based on BVF Inc's 13F filing for Q2 2025, filed 14 Aug 2025.